Loading clinical trials...
Loading clinical trials...
Patients diagnosed with hematologic cancer are at substantial risk of dying, as 5-year survival among patients with acute myeloid leukemia is 20 % and only every second patient treated for incurable m...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Christoffer Johansen
Collaborators
NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more
NCT07053436 · High Risk Newly Diagnosed Multiple Myeloma
NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04728893 · Hematologic Malignancies, Waldenstroms Macroglobulinaemia, and more
NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Aalborg Universitetshospital
Aalborg
Aarhus Universitetshospital
Aarhus
Sydvestjysk sygehus - Esbjerg
Esbjerg
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions